174 related articles for article (PubMed ID: 22376076)
1. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
Parra AL; Rodriguez JC
Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
[TBL] [Abstract][Full Text] [Related]
2. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia.
Rodríguez Cruz Y; Mengana Támos Y; Muñoz Cernuda A; Subirós Martines N; González-Quevedo A; Sosa Testé I; García Rodríguez JC
ScientificWorldJournal; 2010 Nov; 10():2288-300. PubMed ID: 21103798
[TBL] [Abstract][Full Text] [Related]
3. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
Garcia-Rodriguez JC; Sosa-Teste I
ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
[TBL] [Abstract][Full Text] [Related]
4. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
[TBL] [Abstract][Full Text] [Related]
5. Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.
Gao Y; Mengana Y; Cruz YR; Muñoz A; Testé IS; García JD; Wu Y; Rodríguez JC; Zhang C
J Histochem Cytochem; 2011 Feb; 59(2):214-27. PubMed ID: 21339183
[TBL] [Abstract][Full Text] [Related]
6. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
7. Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies.
Hermann DM
ScientificWorldJournal; 2010 Nov; 10():2285-7. PubMed ID: 21103797
[TBL] [Abstract][Full Text] [Related]
8. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
9. Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil.
Teste IS; Tamos YM; Cruz YR; Cernada AM; Rodríguez JC; Martínez NS; Antich RM; González-Quevedo A; Rodríguez JC
ScientificWorldJournal; 2012; 2012():607498. PubMed ID: 22701364
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the delivery of erythropoietin and its variants into the ischemic brain.
Hermann DM
ScientificWorldJournal; 2009 Sep; 9():967-9. PubMed ID: 19768353
[TBL] [Abstract][Full Text] [Related]
11. Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury.
Gan Y; Xing J; Jing Z; Stetler RA; Zhang F; Luo Y; Ji X; Gao Y; Cao G
Stroke; 2012 Nov; 43(11):3071-7. PubMed ID: 22984011
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
Merelli A; Czornyj L; Lazarowski A
Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
[TBL] [Abstract][Full Text] [Related]
13. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
14. [Erythropoietin--a new therapy in cerebral ischemia?].
Kalialis LV; Olsen NV
Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures.
Yoo JY; Won YJ; Lee JH; Kim JU; Sung IY; Hwang SJ; Kim MJ; Hong HN
J Neurosci Res; 2009 Jan; 87(1):150-63. PubMed ID: 18711747
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection with or without erythropoiesis; sometimes less is more.
Torup L
Br J Pharmacol; 2007 Aug; 151(8):1141-2. PubMed ID: 17533424
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic growth factor EPO has neuro-protective and neuro-trophic effects--review].
Zhou ZY; Yang M; Fok TF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):332-7. PubMed ID: 15854305
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin and derivatives: Potential beneficial effects on the brain.
Vittori DC; Chamorro ME; Hernández YV; Maltaneri RE; Nesse AB
J Neurochem; 2021 Sep; 158(5):1032-1057. PubMed ID: 34278579
[TBL] [Abstract][Full Text] [Related]
19. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid.
Lagarto A; Bueno V; Guerra I; Valdés O; Couret M; López R; Vega Y
Exp Toxicol Pathol; 2011 Sep; 63(6):563-7. PubMed ID: 20488687
[TBL] [Abstract][Full Text] [Related]
20. Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.
Castañeda-Arellano R; Feria-Velasco AI; Rivera-Cervantes MC
Neurosci Lett; 2014 Nov; 583():16-20. PubMed ID: 25219375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
